Primary Open Angle Glaucoma Therapeutics
1. Vizz patent expiration
Treatment: Treatment of presbyopia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12414942 | LENZ | NA |
Mar, 2044
(18 years from now) | |
| US10052313 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| US11179328 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| US12128036 | LENZ | Compositions And Methods For Storage Stable Ophthalmic Drugs |
Oct, 2039
(13 years from now) | |
| US9844537 | LENZ | Compositions And Methods For The Treatment Of Presbyopia |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
